Advertisement

Epilepsie pp 115-116 | Cite as

Weiterführende Literatur

  • Gerd Dannhardt
  • Susann Seddigh
  • Thomas Vogt
Part of the Optimierte Arzneimitteltherapie book series (ARZNEIMITTELTH.)

Weiterführende Literatur

  1. Alvarez N, Besag F, Livanainen M (1998) Use of antiepileptic drugs in the treatment of epilepsy in people with intellectuel disability. J Int Dis Res 42:1–15CrossRefGoogle Scholar
  2. Ben-Menachem E et al. (1996) Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 37:539–543PubMedCrossRefGoogle Scholar
  3. Bialer M, Sanjay TW et al. (1999) Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference. Epilepsy Res 34:1–41PubMedCrossRefGoogle Scholar
  4. Browne TR, Kugler AR, Eldon MA (1996) Pharmacology and pharmacokinetics of fosphenytoin. Neurology (Suppl.1) 46:3–7Google Scholar
  5. Dannhardt G (1995) Antiepileptika—Pharmakokinetik und therapeutische Anwendung. Pharm Ztg 140:3227–3236Google Scholar
  6. Dannhardt G (2000) Epilepsie: Hoffnung für die Patienten durch neue Medikamente. Pharm Ztg 145:11–21Google Scholar
  7. Dannhardt G (2000) Epilepsie: Ergänzende und alternative Behandlungsmethoden. Pharm Ztg 145:74Google Scholar
  8. Dannhardt G, vonGruchalla M (1997) Der NMDA-Rezeptor und seine Liganden bei cerebraler Ischämie. Pharm Ztg 142:1359–1374Google Scholar
  9. Dannhardt G, Kohl BK (1998) The glycine site on the NMDA receptor: Structureactivity relationships and possible therapeutic applications. Curr Med Chem 5:253–263PubMedGoogle Scholar
  10. Dannhardt G, Kohl BK (2001) The NMDA Receptor Complex: A promising target for novel antiepileptic strategies. Curr Med Chem 8:1275–1289PubMedCrossRefGoogle Scholar
  11. Gasior M, Ungard JT, Witkin JM (1999) Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures. J Pharmacol Exp Ther 290:1148–1156PubMedGoogle Scholar
  12. Gee NS, Sanjay TW et al. (1996) The novel anticonvulsant drug, gabapentin (neurontin) binds to the.?2.?-subunit of a calcium channel. J Biol Chem 271:5768–5776PubMedCrossRefGoogle Scholar
  13. Grant SM, Faulds D (1992) Oxcarbazepine: A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 43:873–888PubMedCrossRefGoogle Scholar
  14. Hagers Handbuch der Pharmazeutischen Praxis (1993) 5. Auflage, Stoffe Bände 7-9, Folgebände 4 und 5, Springer-Verlag, Berlin, Heidelberg, New YorkGoogle Scholar
  15. Johnson S, Johnson FN (eds.) (1994) Lamotrigine. Rev Contemp Pharmacother 5:67–151Google Scholar
  16. Ketter TA, Sanjay TW et al. (1999) Metabolism and excretion of novel stabilizers and new anticonvulsants. Cell Mol Neurobiol 19:511–532Google Scholar
  17. Klitgaard H, Sanjay TW et al. (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353:191–206PubMedCrossRefGoogle Scholar
  18. Leppik IE (1995) Tiagabine: The safety landscape. Epilepsia (Suppl. 6) 36:10–13CrossRefGoogle Scholar
  19. Löscher W, Schmidt D (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2:45–181Google Scholar
  20. Mallarkey G, Palmer JK (eds.) (1999) Issues in Epilepsy. Adis International Ltd.Google Scholar
  21. Mimaki T (1998) Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 20:593–597PubMedCrossRefGoogle Scholar
  22. Mutschler E (1996) Arzneimittelwirkungen 7. Auflage, Wissenschaftliche Verlagsgesellschaft StuttgartGoogle Scholar
  23. Pellock JM (1999) Felbamate in epilepsy therapy. Drug Safety 225–230.Google Scholar
  24. Pinto F, Tassinari CA (eds.) (1996) Topiramate: New Advances in the treatment of epilepsy. Epilepsia (Suppl. 2) 37:1–23Google Scholar
  25. Sabers A, Gram L (1992) Pharmacology of Vigabatrin. Pharmacol Toxicol 70:237–243PubMedCrossRefGoogle Scholar
  26. Sofia RD (1995) Felbamate, Mechanisms of action. In: Antiepileptic drugs, 4th edition. Raven Press Ltd. 791–800.Google Scholar
  27. Speight TM, Holford NHG (1996) Avery’s Drug Treatments, 4th Edition, Adis InternationalGoogle Scholar
  28. Suzdak PD, Jansen JA (1995) A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 316:612–626CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • Gerd Dannhardt
    • 1
  • Susann Seddigh
    • 2
  • Thomas Vogt
    • 3
  1. 1.Institut für PharmazieJohannes-Gutenberg-UniversitätMainzGermany
  2. 2.DRK SchmerzzentrumMainzGermany
  3. 3.Klinik und Poliklinik für NeurologieMainzGermany

Personalised recommendations